NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., announced today that it has closed the first tranche of its non-brokered private placement, raising C$2.7 million. The company sold 22.5 million units at C$0.12 per unit, each unit consisting of one common share and one common share purchase warrant. Each warrant allows the holder to purchase an additional common share at US$0.115 (approximately C$0.16) until August 12, 2029. The warrants include an acceleration provision: if the company's securities are approved for trading on the Nasdaq Stock Market, the expiry date of 50% of the unexercised warrants will be accelerated, with three business days' written notice provided to holders. The warrants are non-transferable.
The net proceeds from the first tranche are intended for general working capital purposes, including evaluating prospective transactions, settling liabilities, repaying outstanding indebtedness owed to SciSparc Ltd., and covering other corporate and administrative expenses. All securities issued in connection with the first tranche, including shares issuable upon exercise of warrants, are subject to a four-month-and-one-day restricted period from the date of issuance. The offering remains subject to final approval from the TSX Venture Exchange and other applicable regulatory approvals.
In connection with the first tranche, the company paid C$222,750 in finder's fees to a qualified arm's length party, who also received 2,812,500 common shares as compensation. The securities offered have not been registered under the United States Securities Act of 1933, and may not be offered or sold in the United States absent registration or an applicable exemption.
NeuroThera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. The company's work is particularly relevant given the growing need for effective treatments for CNS disorders, which affect millions worldwide. This capital raise will support the company's continued development and potential expansion of its pipeline, which could eventually lead to new therapeutic options for patients.
The offering was previously announced on June 30, 2026, and July 2, 2026. The company has not yet provided details on whether additional tranches of the offering will close, but the first tranche's success indicates investor confidence in its strategy. With the proceeds, NeuroThera aims to strengthen its financial position and pursue opportunities that align with its mission, potentially including strategic partnerships or acquisitions. The repayment of debt to SciSparc Ltd. may also clarify the financial relationship between the parent and subsidiary, which could be positive for corporate governance.
This development is significant for the biotech industry as it reflects ongoing investor interest in CNS-focused therapies, an area with high unmet medical need. For NeuroThera, the funding provides a runway to advance its research and potentially bring new treatments closer to patients. However, as with all clinical-stage companies, the path to commercialization is fraught with risks, including regulatory hurdles and the need for additional financing. The company's forward-looking statements caution that actual results may differ materially from expectations.
The closing of this tranche marks a step forward for NeuroThera as it navigates the complex landscape of drug development. With the funds in hand, the company can continue its work on innovative therapies that may one day improve the lives of those suffering from CNS disorders. Investors and industry watchers will be keen to see how the company utilizes these resources and whether it can achieve its long-term goals.
